Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through United States.